Prostate cancer
Transdermal oestradiol patches as effective as injections for advanced prostate cancer, study finds
Systemic gaps identified in prostate cancer care for men with intellectual disabilities
Baseline PSA levels linked to long-term prostate cancer risk in population study
Registry of patients at high genetic risk of cancer announced to guide screening
NSC advises against whole-population prostate cancer screening
Calls for updated prostate cancer guidance as overtreatment identified
In vitro advances in predicting resistance to PARP inhibitors for BRCA1/2 mutations
Can dietary fibre mitigate prostate cancer radiotherapy side effects?
Saliva test more accurate than PSA level or MRI for prostate cancer risk, study suggests
Biomarker and MRI-enhanced strategies comparable for prostate cancer screening, study finds
AI study reveals prostate cancer consists of two distinct subtypes
PARP inhibitor talazoparib combined with enzalutamide approved in EU for prostate cancer
Stereotactic radiotherapy equivalent to standard care in localised prostate cancer, study finds
5-alpha reductase inhibitor use not linked to prostate cancer mortality